ArticlePloS one2026
Type 2 diabetes and cancer: A retrospective longitudinal comparative cohort study of disease sequence and comorbidity profiles.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 Diabetes Mellitus (T2DM) and cancer are major non-communicable diseases that impose a substantial dual burden when they co-occur. However, this dual burden remains understudied and the majority of existing studies investigate T2DM as a comorbidity without distinguishing whether it is pre-existing at the time of cancer diagnosis or newly-onset following diagnosis. This study aimed to investigate the co-occurrence of T2DM and cancer and to assess differences in laboratory variables, comorbidities, complications and overall survival according to the sequence of diagnosis. This retrospective cohort study with longitudinal follow-up included patients diagnosed with both T2DM and cancer. A total of 213 adult patients who meet the inclusion criteria were categorized based on the sequence of diagnosis: T2DM prior to cancer (n = 131) or cancer prior to T2DM (n = 82). The prevalence of T2DM among in-patients with cancer was 27.4%. Statistical analyses were performed to compare clinical and laboratory characteristics between groups. Breast cancer and colon cancers were the most common cancer types. Most patients were diagnosed with T2DM prior to cancer onset and were significantly older than those diagnosed with cancer first (p = 0.02). Male patients had a higher risk of mortality compared to females (HR = 1.96, p = 0.03). Among patients diagnosed with cancer prior to T2DM, males had significantly higher diastolic blood pressure (p = 0.02), while females had significantly higher total cholesterol levels (p = 0.04). No significant differences were observed in comorbidities or complications between groups (all p > 0.05). There were no significant differences in overall survival between the two diagnostic-order groups (p = 0.03). Moreover, separate survival analysis for breast, colon, lung and gastric cancers showed no significant differences between patients diagnosed with T2DM before cancer and those diagnosed with cancer before T2DM (all p > 0.05). Future studies are warranted to confirm these findings and to better understand the burden of the co-occurrences of T2DM and cancer at national level.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.